flucytosine has been researched along with Local Neoplasm Recurrence in 3 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The indication is local recurrence of prostate cancer after definitive radiation therapy." | 2.70 | Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. ( Aguilar-Cordova, E; Barton, K; Brown, S; DePeralta-Venturina, M; Freytag, SO; Khil, M; Kim, JH; Lu, M; Menon, M; Nafziger, D; Paielli, D; Peabody, J; Pegg, J; Stricker, H, 2002) |
| "Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults." | 2.61 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Philbrick, BD | 1 |
| Adamson, DC | 1 |
| Freytag, SO | 1 |
| Khil, M | 1 |
| Stricker, H | 1 |
| Peabody, J | 1 |
| Menon, M | 1 |
| DePeralta-Venturina, M | 1 |
| Nafziger, D | 1 |
| Pegg, J | 1 |
| Paielli, D | 1 |
| Brown, S | 1 |
| Barton, K | 1 |
| Lu, M | 1 |
| Aguilar-Cordova, E | 1 |
| Kim, JH | 1 |
| Hanna, NN | 1 |
| Mauceri, HJ | 1 |
| Wayne, JD | 1 |
| Hallahan, DE | 1 |
| Kufe, DW | 1 |
| Weichselbaum, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile[NCT00583492] | Phase 2 | 44 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This metric includes both expected and unexpected events Toxicities were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3 (NCT00583492)
Timeframe: 90 days
| Intervention | percentage of adverse events (Number) |
|---|---|
| Gene Therapy + IMRT | 4.6 |
| IMRT Alone | 6.0 |
Quality of Life was measured using the comprehensive Expanded Prostate Cancer Index Composite (EPIC) instrument 19 and 20 (NCT00583492)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 0 |
| IMRT Alone | 0 |
(NCT00583492)
Timeframe: 10 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 21 |
| IMRT Alone | 23 |
Biochemical/Clinical Failure was defined as PSA nadir plus 2 ng/mL (NCT00583492)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 20 |
| IMRT Alone | 21 |
(NCT00583492)
Timeframe: 10 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 21 |
| IMRT Alone | 23 |
(NCT00583492)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 6 |
| IMRT Alone | 11 |
1 review available for flucytosine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi | 2019 |
1 trial available for flucytosine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Topics: Adenoviruses, Human; Aged; Aged, 80 and over; Biopsy; Cytosine Deaminase; DNA, Viral; Flucytosine; G | 2002 |
1 other study available for flucytosine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts.
Topics: Adenoviruses, Human; Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1997 |